Clinical Research at the Istituto Oncologico della Svizzera Italiana
The Clinical Research Unit ( CRU-IOSI) is responsible for managing and coordinating clinical trials involving experimental therapies at all stages of development. The CRU-IOSI serves as the point of contact for all matters related to the conduct of clinical research and supports investigators and various research groups with the goal of improving the quality of clinical research while fostering a culture of innovation.
The New Drug Development Unit of the Istituto Oncologico della Svizzera Italiana, based at the Ospedale San Giovanni in Bellinzona, is specifically dedicated to the development and conduct of Phase I clinical trials, including “first-in-human”) designed to evaluate new drugs and/or innovative therapeutic approaches.
These units are staffed by highly qualified medical and nursing personnel with extensive experience in conducting clinical trials at all stages of development (Phase I–III trials and translational studies). They collaborate with all IOSI units and physicians regarding patients enrolled in clinical trials, as well as with national and international consortia, institutes, and research groups to conduct multicenter clinical trials.
The main areas of clinical research at the Istituto Oncologico della Svizzera Italiana are the development of new drugs, prostate cancer, and lymphatic neoplasms.
Other research areas include breast cancer, lung cancer, hematology research, gastrointestinal cancers, gynecological cancers, melanoma, and radiation therapy research.
